Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study.
Baranda JC, Robbrecht D, Sullivan R, Doger B, Santoro A, Barve M, Grob JJ, Bechter O, Vieito M, de Miguel MJ, Schadendorf D, Johnson M, Pouzin C, Cantalloube C, Wang R, Lee J, Chen X, Demers B, Amrate A, Abbadessa G, Hodi FS.
Baranda JC, et al. Among authors: pouzin c.
Clin Transl Sci. 2024 Jun;17(6):e13854. doi: 10.1111/cts.13854.
Clin Transl Sci. 2024.
PMID: 38898592
Free PMC article.
Clinical Trial.